1
|
Guo S, Li Z, Zheng M, Wu F, Sun J, Tuo L, Li S, Li X, Wei L, Xia Z, Xie P, Chen X, Zhao Y, Gao Y, Yu D. Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China. Vaccine 2024; 42:126183. [PMID: 39088987 DOI: 10.1016/j.vaccine.2024.126183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 07/21/2024] [Accepted: 07/25/2024] [Indexed: 08/03/2024]
Abstract
OBJECTIVES This study aims to evaluate the safety of a new inactivated poliomyelitis vaccine (Sabin strains) (sIPV) for large-scale use in primary and booster immunizations, whether simultaneously administered with other vaccines or not and to explore the persistence of all vaccines at approximately six months after vaccination. METHOD A total of 3200 infants were recruited into this study, including 2000 infants aged 2-3 months randomly assigned (1:1) into the "sIPV basic" or the "sIPV+DTaP" group for primary immunization of sIPV. Another 1200 children aged 18 months old and above were randomly assigned (2:2:1:1) into the "sIPV booster," "sIPV+HepA-I," "sIPV+MMR", or "sIPV+HepA-L" group for booster immunization of sIPV. Adverse events within 30 days of each vaccination dose in all participants were self-reported by guardians using a WeChat mini-program. Approximately 200 blood samples were collected at 5-7 months after the final vaccination to test for antibodies against poliovirus and other viruses. RESULTS 3198 participants in total were included in the safety study, including 1999 infants aged 2-3 months old and 1199 children aged 18-26 months old. For primary immunization, the incidence of adverse reactions in the "sIPV basic" and the "sIPV+DTaP" group were 3.19 and 6.21% (P = 0.001), respectively. For booster immunization, the incidences of adverse reaction for the "sIPV booster" group were 2.25%, while the incidence for the "sIPV +others" group in total was 2.50% (P = 0.788). Most adverse reactions were mild. Fever was the most common symptom in all groups. No vaccine-related serious adverse events (SAEs) were observed in this study. The seropositivity rates of antibodies in the "sIPV basic" and the "sIPV+DTaP" group were 92.31 and 100% against type 1 poliovirus (P = 0.031); 96.15% and 98.57% against type 2 poliovirus (P = 0.575); 98.08% and 91.43% against type 3 poliovirus (P = 0.237), respectively. Regarding booster vaccination with sIPV, whether co-administered with other vaccines or not, the seropositivity rates of antibodies against the three types of polioviruses were all 100%. Seropositivity rates of antibodies against hepatitis A, measles, mumps, and rubella were all no <77%, except for pertussis, which was <30%. CONCLUSION sIPV demonstrated good safety and immune persistence for primary and booster vaccinations, whether administered singly or simultaneously. Antibodies against hepatitis A, measles, mumps and rubella were not disrupted by the co-vaccination. However, the seropositivity rates and geometric mean concentrations (GMCs) of antibodies against pertussis indicate the necessity for a booster dose.
Collapse
Affiliation(s)
- Shicheng Guo
- Jiangxi Provincial Center for Disease Control and Prevention, China
| | | | - Min Zheng
- Jiangxi Provincial Center for Disease Control and Prevention, China
| | - Fengyun Wu
- Jiangxi Provincial Center for Disease Control and Prevention, China
| | | | | | - Su Li
- Pingxiang City Center for Disease Control and Prevention, Jiangxi, China
| | - Xiang Li
- Shangli County Center for Disease Control and Prevention, Jiangxi, China
| | - Lijuan Wei
- Shangli County Center for Disease Control and Prevention, Jiangxi, China
| | - Zhiyong Xia
- Gaoan County Center for Disease Control and Prevention, Jiangxi, China
| | - Pinxing Xie
- Gaoan County Center for Disease Control and Prevention, Jiangxi, China
| | - Xiaomei Chen
- Gaoan County Center for Disease Control and Prevention, Jiangxi, China
| | | | | | - Dan Yu
- Sinovac Biotech Ltd., China.
| |
Collapse
|
2
|
Feng G, Shao M, Wang J, Huang L, Tan J, Jiang Z, You W, Li Y, Yang Y, Li J, Wang Y. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months. Vaccines (Basel) 2024; 12:123. [PMID: 38400106 PMCID: PMC10892248 DOI: 10.3390/vaccines12020123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 12/24/2023] [Accepted: 01/09/2024] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND The multidose Sabin-strain inactivated poliovirus vaccine (sIPV) has the potential to significantly aid in the eradication of poliomyelitis, particularly in low- and middle-income countries. As part of a phase III clinical trial in which infants were given three doses of primary immunization at 2, 3, and 4 months of age, this study aimed to evaluate immune persistence following primary immunization, as well as the safety and immunogenicity of a booster of the 5-dose sIPV in infants aged 18 months. METHODS Infants aged 18 months were given one booster dose of 5-dose sIPV in stage one, which was open-label. Unblinding was performed for stage two after completing primary immunization, which was randomized, blinded, and controlled; infants aged 18 months in the test group I-III, IPV group, and single-dose sIPV group were given one booster dose of 5-dose sIPV, conventional IPV, and single-dose sIPV, respectively, in stage two. RESULTS This study included 1438 infants in the immune persistence and safety set and 1387 infants in the booster per-protocol set. Fourteen months after primary immunization, the seropositivity rates (≥1:8) for types 1-3 were 100%, 99.88%, and 99.53% in the 5-dose sIPV groups; 100%, 98.97%, and 97.23% in the IPV group; and 99.66%, 100%, and 99.66% in the single-dose sIPV group. A total of 30 days after booster immunization, the seropositivity rates (≥1:8) of 3 serotypes in all the groups reached 100%. The geometric mean titers of neutralizing antibodies for types 1-3 in the 5-dose sIPV group were 9962.89, 10273, and 7870.21, with geometric mean increases of 15.76, 33.15, and 24.5, compared to the pre-booster level. The overall incidence of adverse reactions was 8.97%, with fever being the most common, observed at rates of 7.1%, 5.52%, and 7.96% in the 5-dose sIPV, IPV, and single-dose groups, respectively (p = 0.4845). CONCLUSIONS The 5-dose sIPV has shown promising immune persistence and robust immune response following a booster immunization, coupled with an acceptable safety profile.
Collapse
Affiliation(s)
- Guangwei Feng
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Ming Shao
- National Institute for Food and Drug Control, Beijing 100050, China;
| | - Jianfeng Wang
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Lili Huang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Jian Tan
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Zhiwei Jiang
- Beijing Key Tech Statistics Technology, Beijing 100025, China;
| | - Wangyang You
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Yurong Li
- Sinovac Life Sciences Co., Ltd., Beijing 102629, China;
| | - Yonghui Yang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| | - Jing Li
- Sinovac Biotech Co., Ltd., Beijing 100085, China; (J.W.); (J.T.)
| | - Yanxia Wang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450018, China; (G.F.); (L.H.); (W.Y.); (Y.Y.)
| |
Collapse
|
3
|
Kumar P, Bird C, Holland D, Joshi SB, Volkin DB. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication. Hum Vaccin Immunother 2022; 18:2154100. [PMID: 36576132 PMCID: PMC9891683 DOI: 10.1080/21645515.2022.2154100] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Implementation of inactivated polio vaccines (IPV) containing Sabin strains (sIPV) will further enable global polio eradication efforts by improving vaccine safety during use and containment during manufacturing. Moreover, sIPV-containing vaccines will lower costs and expand production capacity to facilitate more widespread use in low- and middle-income countries (LMICs). This review focuses on the role of vaccine formulation in these efforts including traditional Salk IPV vaccines and new sIPV-containing dosage forms. The physicochemical properties and stability profiles of poliovirus antigens are described. Formulation approaches to lower costs include developing multidose and combination vaccine formats as well as improving storage stability. Formulation strategies for dose-sparing and enhanced mucosal immunity include employing adjuvants (e.g. aluminum-salt and newer adjuvants) and/or novel delivery systems (e.g. ID administration with microneedle patches). The potential for applying these low-cost formulation development strategies to other vaccines to further improve vaccine access and coverage in LMICs is also discussed.
Collapse
Affiliation(s)
- Prashant Kumar
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA
| | - Christopher Bird
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA
| | - David Holland
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA
| | - Sangeeta B. Joshi
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA
| | - David B. Volkin
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA,CONTACT David B. Volkin Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Multidisciplinary Research Building, 2030 Becker Drive, Lawrence, KS66047, USA
| |
Collapse
|
4
|
Wang Y, Xu Q, Jeyaseelan V, Ying Z, Mach O, Sutter R, Wen N, Rodewald L, Li C, Wang J, Yuan H, Yin Z, Feng Z, Xu A, An Z. Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial. THE LANCET REGIONAL HEALTH. WESTERN PACIFIC 2021; 10:100133. [PMID: 34327346 PMCID: PMC8315596 DOI: 10.1016/j.lanwpc.2021.100133] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 02/22/2021] [Accepted: 03/04/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).
Collapse
Affiliation(s)
- Yamin Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qing Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Vishali Jeyaseelan
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Zhifang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Ondrej Mach
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Roland Sutter
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Ning Wen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Changgui Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Jie Wang
- Dezhou prefecture-level Center for Disease Control and Prevention, Dezhou, Shandong, China
| | - Hui Yuan
- Liaocheng prefecture-level Center for Disease Control and Prevention, Liaocheng, Shandong, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Aiqiang Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
5
|
Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial. Vaccine 2018; 36:6782-6789. [DOI: 10.1016/j.vaccine.2018.09.023] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2017] [Revised: 09/11/2018] [Accepted: 09/12/2018] [Indexed: 11/21/2022]
|
6
|
Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis. Hum Vaccin Immunother 2018; 14:2636-2643. [PMID: 29985751 DOI: 10.1080/21645515.2018.1489188] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
BACKGROUND The emergence of vaccine-associated paralytic poliomyelitis has become an ongoing burden of poliomyelitis. During this special period from OPV to IPV-only immunization schedule, we did a meta-analysis to compare the immunogenicity of sequential IPV and OPV versus IPV alone in healthy infants. METHODS This systematic review and meta-analysis was registered at international prospective register of systematic reviews (PROSPERO), and the number was CRD42017054889. We performed it as described. RESULTS Finally, 6 articles were qualified for our review. The results showed that seroconversion rates against all 3 serotype polioviruses were non-inferior and Geometric mean antibody titers (GMTs) were superior in sequential schedules compared with IPV-only schedule. Thus, the sequential vaccination schedules could induce a stronger immunogenicity. CONCLUSIONS To decrease vaccine-associated and vaccine-derived poliomyelitis, it is a reasonable option to select sequential schedules during this special transition from OPV to IPV-only immunization schedule, which coincides with the current WHO recommendations.
Collapse
Affiliation(s)
- Guihua Tang
- a Department of Clinical Laboratory , Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University) , Changsha , Hunan Province , China
| | - Wen Yin
- b Department of Neurosurgery , Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| | - Youde Cao
- a Department of Clinical Laboratory , Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University) , Changsha , Hunan Province , China
| | - Liming Tan
- a Department of Clinical Laboratory , Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University) , Changsha , Hunan Province , China
| | - Shuyu Wu
- b Department of Neurosurgery , Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| | - Yudong Cao
- b Department of Neurosurgery , Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| | - Xianyong Fu
- b Department of Neurosurgery , Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| | - Jing Yan
- c Department of Ultrasound , Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University) , Changsha , Hunan Province , China
| | - Xingjun Jiang
- b Department of Neurosurgery , Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| |
Collapse
|
7
|
Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, Ying Z, Wang J, Yang H, Ma Y, Ma L, Ji G, Shi L, Jiang S, Li Q. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses. Clin Infect Dis 2017; 64:1317-1325. [DOI: 10.1093/cid/cix110] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Accepted: 02/08/2017] [Indexed: 01/08/2023] Open
Affiliation(s)
- Mingbo Sun
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Changgui Li
- Third Division of Viral Vaccines, National Institutes for Food and Drug Control, and
| | - Wenbo Xu
- Ministry of Health Key Laboratory for Medical, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing,
| | - Guoyang Liao
- No. 5 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Rongcheng Li
- Vaccine Clinical Research Center, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, and
| | - Jian Zhou
- No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
| | - Yanping Li
- Vaccine Clinical Research Center, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, and
| | - Wei Cai
- No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
| | - Dongmei Yan
- Ministry of Health Key Laboratory for Medical, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing,
| | - Yanchun Che
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Zhifang Ying
- Third Division of Viral Vaccines, National Institutes for Food and Drug Control, and
| | - Jianfeng Wang
- Third Division of Viral Vaccines, National Institutes for Food and Drug Control, and
| | - Huijuan Yang
- No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
| | - Yan Ma
- No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
| | - Lei Ma
- No. 5 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Guang Ji
- No. 4 Department of Biological Products, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
| | - Li Shi
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Shude Jiang
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| | - Qihan Li
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan,
| |
Collapse
|
8
|
Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2014; 34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Revised: 10/29/2014] [Accepted: 11/07/2014] [Indexed: 12/19/2022]
Abstract
During the endgame of global polio eradication, the universal introduction of inactivated poliovirus vaccines is urgently required to reduce the risk of vaccine-associated paralytic poliomyelitis and polio outbreaks due to wild and vaccine-derived polioviruses. In particular, the development of inactivated poliovirus vaccines (IPVs) derived from the attenuated Sabin strains is considered to be a highly favorable option for the production of novel IPV that reduce the risk of facility-acquired transmission of poliovirus to the communities. In Japan, Sabin-derived IPVs (sIPVs) have been developed and introduced for routine immunization in November 2012. They are the first licensed sIPVs in the world. Consequently, trivalent oral poliovirus vaccine was used for polio control in Japan for more than half a century but has now been removed from the list of vaccines licensed for routine immunization. This paper reviews the development, introduction, characterization, and global status of IPV derived from attenuated Sabin strains.
Collapse
|